A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer.
M1/M2 macrophage
Prostate cancer
experimental therapeutic
solid tumors
suppressive cells
tumor-associated macrophage.
Journal
Current drug targets
ISSN: 1873-5592
Titre abrégé: Curr Drug Targets
Pays: United Arab Emirates
ID NLM: 100960531
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
11
2018
revised:
18
01
2019
accepted:
20
01
2019
pubmed:
25
1
2019
medline:
28
7
2020
entrez:
25
1
2019
Statut:
ppublish
Résumé
Prostate cancer is malignant cancer leading to high mortality in the male population. The existence of suppressive cells referred to as tumor-associated macrophages (TAM) is a major obstacle in prostate cancer immunotherapy. TAMs contribute to the immunosuppressive microenvironment that promotes tumor growth and metastasis. In fact, they are main regulators of the complicated interactions between tumor and surrounding microenvironment. M2 macrophages, as a type of TAMs, are involved in the growth and progression of prostate cancer. Recently, they have gained remarkable importance as therapeutic candidates for solid tumors. In this review, we will discuss the roles of M2 macrophages and worth of their potential targeting in prostate cancer treatment. In the following, we will introduce important factors resulting in M2 macrophage promotion and also experimental therapeutic agents that may cause the inhibition of prostate cancer tumor growth.
Identifiants
pubmed: 30674255
pii: CDT-EPUB-96042
doi: 10.2174/1389450120666190123141553
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
789-798Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.